Rationale & Objective: Studies of immunoglobulin A nephropathy (IgAN) have suggested the therapeutic benefit of simultaneously adding tonsillectomy to corticosteroid therapy. However, the efficacy of tonsillectomy monotherapy in the absence of simultaneous use of corticosteroids is unclear.

Study Design: Patients with IgAN treated with tonsillectomy monotherapy were analyzed retrospectively. Clinical parameters, including kidney function slope, were compared before and after tonsillectomy.

Setting & Participants: Patients with biopsy-proven IgAN who received tonsillectomy monotherapy at our hospital between 2007 and 2018.

Results: 20 Japanese patients with IgAN were included in this study (mean follow-up period, 135 months from initial biopsy diagnosis to tonsillectomy). All patients had been treated with renin-angiotensin-aldosterone system inhibitors. 17 patients had a history of induction therapy with corticosteroids. Mean time to tonsillectomy from termination of corticosteroid therapy was 84 months. Hematuria, proteinuria, and clinical remission were achieved in 13 of 17 (76%), 10 of 17 (59%), and 8 of 20 (40%) patients at medians of 3.0, 6.0, and 13.5 months, respectively, after tonsillectomy. The slope of the estimated glomerular filtration rate (eGFR) increased significantly during the 81-month observation period, including the periods before and after tonsillectomy (−2.59 vs 1.05 mL/min/1.73 m² per year; P < 0.001). The effect on eGFR slope was consistent in 11 patients with reduced GFR (eGFR < 60 mL/min/1.73 m²) at the time of tonsillectomy (−3.07 vs −0.39 mL/min/1.73 m² per year; P < 0.001).

Limitations: Small sample size. Lack of a control (no-tonsillectomy) group due to the difficulty of setting the baseline time point (which corresponded to tonsillectomy in our sample). Potential exclusion of patients with the most severe disease who are likely to receive corticosteroids. Lack of generalizability to patients in other countries.

Conclusions: Tonsillectomy monotherapy may prevent kidney function decline in some patients with IgAN who received tonsillectomy monotherapy. All patients showed persistent urinalysis abnormalities and/or established reduced GFR (estimated GFR [eGFR] < 60 mL/min/1.73 m²) despite long-term treatment of IgAN.

METHODS

Patient Selection
This study included adult patients with biopsy-proven IgAN who received tonsillectomy monotherapy (without simultaneous use of corticosteroids) at our hospital between 2007 and 2018. Indications for tonsillectomy were: (1) clinically apparent habitual tonsillitis and/or (2) subclinical chronic tonsillitis based on laryngoscopy findings by otolaryngologists. The patient selection process is shown in Figure 1. Criteria for inclusion were persistent...
Immunoglobulin A nephropathy (IgAN) is a major cause of end-stage kidney disease worldwide. The underlying cause of IgAN remains largely unknown, but basic studies have suggested the involvement of mucosal immunity of palatine tonsils. Tonsillectomy has been performed for the treatment of IgAN for many years, but its effectiveness remains unclear. This is probably because tonsillectomy for IgAN is often performed with concurrent steroid therapy. This study compared urinalysis abnormalities (hematuria and proteinuria) and speed of glomerular filtration rate (GFR) decline (estimated GFR [eGFR] slope) before and after tonsillectomy monotherapy in patients with IgAN. Both urinalysis abnormalities and eGFR slope were improved by tonsillectomy. This new finding suggests that tonsillectomy is an effective and promising treatment option for patients with IgAN.

Definitions
Hypertension was defined as systolic blood pressure > 140 mm Hg, diastolic blood pressure > 90 mm Hg, or use of antihypertensive medications. Patients prescribed RAAS inhibitors for renoprotection despite having normal blood pressure were not regarded as having hypertension. Treatment with RAAS inhibitors was defined as use of an angiotensin-converting enzyme inhibitor or angiotensin type 1 receptor blocker. Immunosuppressive induction therapy was defined as use of any immunosuppressive agent, including corticosteroids, within 1 year after the initial diagnostic kidney biopsy, irrespective of duration or dose. eGFR was calculated from serum creatinine (Scr) level using a modified equation for Japanese individuals: 
\[
eGFR = 194 \times \text{age}^{-0.287} \times \text{Scr}^{-1.094} \times (0.739 \text{ if female}).
\]
Reduced GFR was defined as eGFR < 60 mL/min/1.73 m². Creatinine clearance rate was measured using Scr and urine creatinine concentrations in a 24-hour urine collection. UPE, urinary sodium excretion, and estimated protein intake were measured in a 24-hour urine collection. RBC count in urinary sediment was graded as follows: 0, <5 RBC/HPF; 1, 5 to 9 RBC/HPF; 2, 10 to 19 RBC/HPF; 3, 20 to 49 RBC/HPF; 4, 50 to 99 RBC/HPF; and 5, >99 RBC/HPF. Remission of urinary abnormalities was defined as reported previously, using data from 3 consecutive visits at 3-month or longer intervals. Hematuria remission was defined as RBC count in urinary sediment of <5 RBC/HPF. Proteinuria remission was defined as UPE < 0.3 g/d. Clinical remission was defined as remission of both hematuria and proteinuria. Patients in remission according to urinalysis findings at the time of tonsillectomy were excluded from the analysis of remission status after tonsillectomy. To evaluate hematuria, proteinuria, and other laboratory parameters, we used median or mean values determined at follow-up visits during the same years’ follow-up with conventional therapies and 1 or more year of observation before and after tonsillectomy.

Figure 1. Patient selection. Abbreviations: IgA, immunoglobulin A; IgAN, immunoglobulin A nephropathy.
observation periods before and after tonsillectomy (Fig S1). eGFR slope (ΔeGFR) was defined as rate of change in eGFR at follow-up visits, calculated using a linear regression model and the least-squares principle (Fig S2).

### Statistical Analysis

Continuous variables are expressed as mean ± standard deviation or median [interquartile range (IQR)]. Conversion factors for units; serum creatinine in mg/dL to μmol/L, ×88.4; cholesterol in mg/dL to mmol/L, ×0.02586. Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin type 1 receptor blocker; BMI, body mass index; Clcr, creatinine clearance; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; IgA, immunoglobulin A; LDL, low-density lipoprotein; RAAS, renin-angiotensin-aldosterone system; RBC, red blood cell; UPE, urinary protein excretion.

*Japanese Clinical Grade classification: C-grade I, UPE < 0.5 g/d and eGFR ≥ 60 mL/min/1.73 m²; C-grade II, UPE ≥ 0.5 g/d and eGFR ≥ 60 mL/min/1.73 m²; C-grade III, eGFR < 60 mL/min/1.73 m².*  

### RESULTS

#### Clinical Characteristics at Tonsillectomy

Clinical characteristics of patients at the time of tonsillectomy are shown in Table 1. The sample comprised 20 patients; men predominated, and mean age was 42 years. All patients had recurrent or persistent urinary abnormalities and/or reduced GFR at the time of tonsillectomy. Urinalysis showed that median grade of the RBC count in urine sediment was 1.0 (IQR, 0.0–3.0) and median UPE was 468 (IQR, 288–532) mg/d. The mean follow-up period from initial biopsy diagnosis to tonsillectomy was 135 months. All 20 patients had been treated with RAAS inhibitors. Seventeen patients had a history of induction therapy with corticosteroids; the time from the termination of corticosteroid therapy to tonsillectomy was 84 months. All patients had recurrent or persistent urinary abnormalities and/or reduced GFR at the time of tonsillectomy. Urinalysis showed that median grade of the RBC count in urine sediment was 1.0 (IQR, 0.0–3.0) and median UPE was 468 (IQR, 288–532) mg/d. The mean follow-up period from initial biopsy diagnosis to tonsillectomy was 135 months. All 20 patients had been treated with RAAS inhibitors. Seventeen patients had a history of induction therapy with corticosteroids; the time from the termination of corticosteroid therapy to tonsillectomy was 84 months.

### Table 1. Clinical and laboratory findings at tonsillectomy

| Characteristics (n = 20) | All (n = 20) | eGFR ≥ 60 (n = 9) | eGFR < 60 (n = 11) |
|-------------------------|-------------|------------------|-------------------|
| **Clinical findings**   |             |                  |                   |
| Men                     | 13 (65%)    | 7 (78%)          | 6 (55%)           |
| BMI, kg/m²              | 21.3 ± 2.8  | 20.6 ± 2.9       | 21.7 ± 2.8        |
| Hypertension            | 1 (5%)      | 0 (0%)           | 1 (9%)            |
| Age at biopsy diagnosis, y | 31.1 ± 12.6 | 23.8 ± 10.6      | 37.1 ± 11.9       |
| Age at tonsillectomy, y | 42.2 ± 11.4 | 34.4 ± 7.7       | 48.6 ± 10.0       |
| Observation period from diagnosis to tonsillectomy, mo | 134.7 ± 61.9 | 129.4 ± 62.2 | 139.0 ± 64.4 |
| Observation period before and after tonsillectomy, mo | 40.5 ± 13.5 | 41.3 ± 16.3 | 39.8 ± 11.5 |
| Antiplatelet use        | 10 (50%)    | 6 (67%)          | 4 (36%)           |
| RAAS inhibitor use      | 20 (100%)   | 9 (100%)         | 11 (100%)         |
| – ACE inhibitor         | 0 (0%)      | 0 (0%)           | 0 (0%)            |
| – ARB                   | 20 (100%)   | 9 (100%)         | 11 (100%)         |
| History of corticosteroid therapy | 17 (85%) | 7 (78%) | 10 (91%) |
| History of corticosteroid pulse therapy | 6 (30%) | 1 (17%) | 5 (50%) |
| Period from termination of corticosteroid therapy to tonsillectomy, mo | 84.3 ± 55.5 | 69.2 ± 39.1 | 93.3 ± 63.6 |
| **Laboratory findings** |             |                  |                   |
| Serum creatinine, mg/dL | 1.18 ± 0.40 | 0.91 ± 0.22      | 1.39 ± 0.40       |
| eGFR, mL/min/1.73 m²    | 57.9 ± 23.8 | 78.0 ± 19.5      | 41.6 ± 10.6       |
| Clcr, mL/min/1.73 m²    | 80.9 ± 25.2 | 93.8 ± 26.3      | 70.3 ± 19.4       |
| Serum IgA, mg/dL        | 260 ± 60.8  | 329 ± 100        | 282 ± 111         |
| Serum IgA/C3 ratio      | 3.1 ± 1.0   | 3.3 ± 0.4        | 3.3 ± 1.6         |
| Serum albumin, g/dL     | 4.1 ± 0.4   | 4.1 ± 0.4        | 4.1 ± 0.4         |
| LDL cholesterol, mg/dL  | 106 ± 33.5  | 104 ± 38.2       | 107 ± 32.7        |
| HDL cholesterol, mg/dL  | 78 ± 27     | 74 ± 29          | 81 ± 28           |
| Serum uric acid, mg/dL  | 6.1 ± 1.3   | 5.2 ± 0.75       | 6.6 ± 1.2         |
| UPE, mg/d               | 468 [288-532] | 515 [345-552] | 440 [282-521] |
| Urinary RBC counts, 0/1/2/3/4/5 grade | 8/4/1/3/4/0 | 1/2/0/2/4/0 | 7/2/1/1/0/0 |
| Japanese Clinical Grade | 4/5/11 | 4/5/0 | 0/0/1 |

*Note:* Data for categorical variables expressed as number (percent); data for continuous variables expressed as mean ± standard deviation or median [interquartile range].
| Case No. | Sex | Age, y | eGFR, mL/min/1.73 m² | Urinary RBC count, grade | UPE, mg/d | Past Corticosteroid Use | Past Pulse Dose Corticosteroid Use | Antiplatelets | RAAS Inhibitors | Diagnosis to Tonsillectomy, mo | Interval From Last Corticosteroids, mo | Observations Before and After Tonsillectomy, mo |
|----------|-----|--------|----------------------|--------------------------|-----------|------------------------|-----------------------------------|--------------|------------------|-------------------------------|------------------------------------------|-----------------------------------------------|
| 1        | M   | 40s    | 71                   | 1                        | 520       | +                      | −                                 | Dipyridamole | Telmisartan       | 223                          | 240                                      | 54                              |
| 2        | M   | 30s    | 62                   | 0                        | 552       | +                      | −                                 | Dilazep      | Losartan          | 174                          | 98                                       | 48                              |
| 3        | M   | 40s    | 71                   | 1                        | 195       | −                      | −                                 | Dipyridamole | Losartan          | 66                           | NA                                       | 33                              |
| 4        | M   | 30s    | 82                   | 3                        | 385       | −                      | −                                 | −            | −                | 158                          | NA                                       | 30                              |
| 5        | M   | 40s    | 66                   | 4                        | 345       | +                      | −                                 | −            | Losartan          | 90                           | 83                                       | 57                              |
| 6        | F   | 20s    | 103                  | 3                        | 515       | +                      | −                                 | Dipyridamole | Losartan          | 183                          | 120                                      | 63                              |
| 7        | M   | 40s    | 70                   | 4                        | 836       | +                      | +                                 | −            | Losartan          | 37                           | 29                                       | 45                              |
| 8        | F   | 20s    | 117                  | 4                        | 288       | +                      | −                                 | Dipyridamole | Losartan          | 85                           | 20                                       | 30                              |
| 9        | M   | 30s    | 60                   | 4                        | 633       | +                      | −                                 | −            | Losartan          | 149                          | 65                                       | 12                              |
| Cases 1-9 |     |        | 34.4 ± 7.7           | 78.0 ± 19.5              | 3.0 [1.0-4.0] | 515 [345-552] | 7 (77%) | 1 (11%) | 6 (67%) | 9 (100%) | 129 ± 62 | 70 ± 77 | 41.3 ± 16.3 |
| eGFR<60mL/min/1.73m² at Tonsillectomy | | | | | | | | | | | | |
| 10       | F   | 50s    | 28                   | 1                        | 900       | +                      | −                                 | −            | Losartan          | 191                          | 165                                      | 42                              |
| 11       | F   | 40s    | 43                   | 0                        | 216       | +                      | −                                 | −            | Losartan          | 193                          | 151                                      | 54                              |
| 12       | F   | 40s    | 44                   | 2                        | 288       | +                      | +                                 | Dilazep      | Losartan          | 219                          | 200                                      | 60                              |
| 13       | F   | 40s    | 44                   | 0                        | 496       | +                      | +                                 | −            | Olmesartan        | 120                          | 83                                       | 39                              |
| 14       | M   | 50s    | 39                   | 0                        | 525       | +                      | +                                 | Dilazep      | Losartan          | 70                           | 64                                       | 45                              |
| 15       | M   | 40s    | 29                   | 0                        | 352       | +                      | −                                 | Dipyridamole | valsartan         | 142                          | 29                                       | 45                              |
| 16       | M   | 30s    | 53                   | 0                        | 113       | −                      | −                                 | −            | Candesartan       | 34                           | NA                                       | 30                              |
| 17       | F   | 40s    | 54                   | 1                        | 440       | +                      | −                                 | −            | Losartan          | 179                          | 126                                      | 30                              |
| 18       | M   | 50s    | 57                   | 3                        | 2543      | +                      | −                                 | −            | Olmesartan        | 131                          | 12                                       | 42                              |
| 19       | M   | 50s    | 41                   | 0                        | 276       | +                      | +                                 | −            | Losartan          | 200                          | 63                                       | 21                              |
| 20       | M   | 70s    | 26                   | 0                        | 516       | +                      | +                                 | Dipyridamole | Losartan          | 50                           | 40                                       | 30                              |
| Cases 10-20 | | | 48.6 ± 10.0 | 41.6 ± 10.6 | 0.0 [0.0-1.0] | 440 [282-521] | 10 (91%) | 5 (45%) | 4 (36%) | 11 (100%) | 139 ± 64 | 86 ± 71 | 39.8 ± 11.5 |

Note: Data for categorical variables are expressed as number (percent); data for continuous variables are expressed as mean ± standard deviation or median [interquartile range].

Abbreviations: eGFR, estimated glomerular filtration rate; F, female; HPF, high-power field; M, male; NA, not available; RAAS, renin-angiotensin-aldosterone system; RBC, red blood cell; UPE, urinary protein excretion.

*Grades of RBC counts in urinary sediment are: 0, <5 RBC/HPF; 1, 5 to 9 RBC/HPF; 2, 10 to 19 RBC/HPF; 3, 20 to 49 RBC/HPF; 4, 50 to 99 RBC/HPF; and 5, >99 RBC/HPF.
months. No patient received an immunosuppressant other than corticosteroids.

Clinical characteristics of 9 patients with preserved kidney function (eGFR ≥ 60 mL/min/1.73 m²) and 11 patients with reduced kidney function (eGFR < 60 mL/min/1.73 m²) at the time of tonsillectomy are shown in Table 2.

### Laboratory Findings Before and After Tonsillectomy

Time-averaged values for laboratory findings obtained before and after tonsillectomy are provided in Table 3. Fourteen (70%) and 16 (80%) of the 20 patients showed reductions in hematuria and proteinuria, respectively. Twelve of 14 (86%) patients showed decreases in serum IgA levels. Overall, the grade of the RBC count in urinary sediment, UPE, and serum IgA level decreased significantly after tonsillectomy relative to pretonsillectomy values; no such difference in mean urinary sodium excretion or estimated protein intake values was observed.

### Achievement of Urinalysis Remission After Tonsillectomy

Patients’ remission status after tonsillectomy according to urinalysis findings is shown in Figure 2. Hematuria, proteinuria, and clinical remission occurred in 13 of 17 (76%), 10 of 18 (57%), and 8 of 20 (40%) patients at a median of 3.0, 6.0, and 13.5 months, respectively, after tonsillectomy.

---

**Table 3. Time-Averaged Laboratory Values Before and After Tonsillectomy**

| Case No. | Urinary RBC Count, grade | UPE, mg/d | % Change | Serum IgA, mg/dL | % Change |
|----------|--------------------------|-----------|----------|-----------------|----------|
|          | Before | After | Before | After | Before | After | Before | After |
| eGFR≥60mL/min/1.73m² at Tonsillectomy | | | | | | | | |
| 1 | 1 | 0 | 655 | 190 | -71.0 | 268 | 266 | -0.7 |
| 2 | 3 | 0 | 486 | 93 | -60.8 | 251 | 188 | -25.1 |
| 3 | 1 | 0 | 323 | 312 | -3.6 | NA | NA | NA |
| 4 | 1.5 | 0 | 577 | 117 | -79.7 | 248 | 214 | -13.9 |
| 5 | 4 | 3 | 500 | 306 | -38.7 | 217 | 207 | -4.8 |
| 6 | 3 | 1 | 598 | 913 | 52.5 | 309 | 216 | -30.0 |
| 7 | 3 | 3 | 484 | 304 | -37.1 | 232 | 233 | 0.8 |
| 8 | 1 | 0 | 328 | 95 | -70.9 | 193 | 159 | -17.2 |
| 9 | 4 | 2 | 1233 | 543 | -55.9 | 393 | 270 | -31.5 |

| eGFR<60mL/min/1.73m² at Tonsillectomy | | | | | | | | |
| 10 | 0 | 0 | 628 | 539 | -14.2 | 288 | 297 | 3.1 |
| 11 | 2 | 0 | 781 | 533 | -31.8 | 266 | 256 | -3.9 |
| 12 | 0.5 | 0 | 324 | 265 | -18.2 | 340 | 290 | -14.6 |
| 13 | 0 | 0 | 791 | 173 | -78.1 | 331 | NA | NA |
| 14 | 1 | 0 | 475 | 304 | -36.0 | 383 | 356 | -6.8 |
| 15 | 1 | 0 | 1,446 | 330 | -77.2 | 358 | 340 | -4.9 |
| 16 | 1 | 0 | 473 | 547 | 15.8 | NA | NA | NA |
| 17 | 1 | 1 | 1,409 | 243 | -82.8 | NA | NA | NA |
| 18 | 1 | 0 | 1,530 | 956 | -37.5 | 348 | 343 | -1.5 |
| 19 | 0 | 0 | 645 | 992 | 53.8 | NA | NA | NA |
| 20 | 0 | 0 | 666 | 884 | 32.6 | NA | NA | NA |

**Note:** Before and after indicates mean or median values before and after tonsillectomy, respectively. Percentage change was defined as follows:

$$\frac{(\text{Time-averaged value after tonsillectomy}) - (\text{Time-averaged value before tonsillectomy})}{(\text{Time-averaged value before tonsillectomy})} \times 100 \,(\%) .$$

Grades of RBC counts in urinary sediment are: 0, <5 RBC/HPF; 1, 5 to 9 RBC/HPF; 2, 10 to 19 RBC/HPF; 3, 20 to 49 RBC/HPF; 4, 50 to 99 RBC/HPF; and 5, 99 RBC/HPF.

Abbreviations: eGFR, estimated glomerular filtration rate; HPF, high-power field; IgA, immunoglobulin A; NA, not available; RBC, red blood cell; UPE, urinary protein excretion.

*Median value.*

*Mean value.*

*Values for serum IgA levels were missing for 6 patients and analyses were performed in 14 patients.

*Statistically significant.*
Changes in Kidney Function Slope After Tonsillectomy

Compared with the pretonsillectomy value, ΔeGFR after tonsillectomy was significantly greater (−2.59 vs 1.05 mL/min/1.73 m² per year; P < 0.001; Fig 3). This increase in ΔeGFR was significant in the 11 patients with reduced GFR (eGFR < 60 mL/min/1.73 m²) at the time of tonsillectomy (−3.07 vs −0.39 mL/min/1.73 m² per year; P < 0.001).

DISCUSSION

Among 20 patients with IgAN and an incomplete response to conventional therapy, tonsillectomy was associated with improvements in hematuria, proteinuria, and eGFR decline. For this retrospective case series, we recruited 20 patients with biopsy-proven IgAN who underwent tonsillectomy without simultaneous use of corticosteroids and analyzed their clinical courses before and after tonsillectomy. All patients showed recurrent or persistent hematuria/proteinuria and/or concomitant GFR decline despite receiving conventional therapies for many years. Compared with pretonsillectomy, time-averaged values for hematuria grade, proteinuria, and ΔeGFR were significantly improved after tonsillectomy. The results suggest that tonsillectomy is beneficial in patients whose disease is resistant to conventional therapies. In addition, the results are consistent with

Figure 2. Remission status according to urinalysis findings after tonsillectomy. (A) Hematuria remission, (B) proteinuria remission, and (C) clinical remission after tonsillectomy were analyzed using log-rank test. Abbreviation: eGFR, estimated glomerular filtration rate.

Figure 3. Slopes of eGFR before and after tonsillectomy. Estimated glomerular filtration rate (eGFR) slopes (ΔeGFRs) were calculated before and after tonsillectomy using a linear regression model. The same color in the left and right panels indicates the same patient, and the black dashed line indicates the mean value for all patients.
previous reports that attenuation of the decline in kidney function in IgAN is associated closely with the remission or regression of hematuria/proteinuria.\textsuperscript{26–28}

Since the first case was reported in the 1980s, much knowledge has accumulated on the effect of tonsillectomy in patients with IgAN.\textsuperscript{29,30} The cellular and molecular mechanisms underlying the effects of tonsillectomy on urinary abnormalities and associated kidney function decline are under investigation. Recent studies have revealed that aberrantly glycosylated IgA and mucosal immunity are involved in the pathogenesis of IgAN.\textsuperscript{1,2,13} The IgA produced by tonsillar lymphocytes has the same aberrant glycosylation pattern as IgA deposits on glomeruli.\textsuperscript{14} Hotta et al\textsuperscript{31} demonstrated that IgA identified in initial diagnostic biopsies was no longer present in serial kidney biopsies performed after tonsillectomy plus corticosteroid pulse therapy. These findings suggest that tonsillar lymphocytes produce aberrantly glycosylated IgA, which is associated with the pathogenesis of glomerulonephritis. Interestingly, the resected tonsils of all 20 patients in the present study were diagnosed histopathologically with chronic tonsillitis. However, only a minority of the patients showed clinically identifiable features of recurrent tonsillitis, consistent with a recent report that tonsil size does not correlate with disease severity or the therapeutic effect of tonsillectomy in patients with IgAN.\textsuperscript{32}

The strengths of this study include the long-term observation of patients with slowly progressive reduction in GFR before tonsillectomy, which enabled comparison of the clinical courses before and after tonsillectomy. Consistent with previous reports, beneficial effects of tonsillectomy on urinary abnormalities and GFR decline were observed in patients with and without reduced GFR at the time of tonsillectomy.\textsuperscript{19,24} Of note, remission rates for urinary abnormalities and improvement in \(\Delta eGFR\) were greater in patients with preserved GFR. In this study, the difference in \(\Delta eGFR\) before and after tonsillectomy correlated positively with eGFR at the time of tonsillectomy (Fig S3). More patients with preserved GFR at the time of tonsillectomy achieved proteinuria remission than those with reduction in GFR at the time of tonsillectomy (Fig S4). Thus, tonsillectomy may provide greater benefit to patients with preserved GFR.

In this study, remission or regression of urinary abnormalities after tonsillectomy occurred without the use of additional immunosuppressive agents, including corticosteroids. Interestingly, most patients showed regression of \(\Delta eGFR\) after tonsillectomy relative to the pretonsillectomy value; the mechanisms underlying this regression are unclear. Most previous studies of tonsillectomy in patients with IgAN involved combination therapy with corticosteroids; thus, the effect of tonsillectomy might have been masked by the immunosuppressive effect of corticosteroids. In this respect, our observations likely reflect the effect of tonsillectomy on chronic IgAN. Thus, tonsillectomy monotherapy may be an option for patients with IgAN who are at greater risk for adverse effects of corticosteroids, particularly those treated previously with corticosteroids.\textsuperscript{15–17} The advantages of tonsillectomy monotherapy are reductions in lifetime recurrence risk and adverse effects of corticosteroids.\textsuperscript{28} A prospective controlled trial of tonsillectomy with and without corticosteroid therapy is required to evaluate this hypothesis.

This study has several limitations. First, we could not include a control (no-tonsillectomy) group due to the difficulty setting the baseline time point (which corresponded to tonsillectomy in our sample). The improvements in urinary abnormalities may have reflected natural remission or disease burn-out during the follow-up period in some patients. Second, inclusion of a small number of patients and lack of patients who did not achieve the kidney outcome may have introduced bias. Third, kidney histopathologic parameters were difficult to analyze due to the intervals between biopsy diagnosis and tonsillectomy (Table S1). Finally, the retrospective design may have resulted in selection bias. Patients with rapid deterioration in kidney function and those with severe proteinuria would be preferentially given corticosteroid therapy and might not have been included in the study population.

In conclusion, tonsillectomy monotherapy may improve urinary abnormalities and slow kidney function decline in some patients with IgAN who may be resistant to conventional therapies and could therefore be an effective therapy for such patients. Further studies will provide additional insight on treatments suitable for patients with IgAN at risk for both progression to end-stage kidney disease and the adverse effects of corticosteroids.
REFERENCES

1. McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant. 2011;26(2):414-430.

2. Pozzi C, Bolaso PC, Fogazzi GB, et al. Corticosteroids in IgA nephropathy. A randomised controlled trial. Lancet. 1999;353(9156):883-887.

3. Coppo R, Peruzzi L, Amore A, et al. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol. 2007;18(6):1880-1888.

4. Samuels JA, Strippoli GF, Craig JC, Schena FP, Molony DA. Immunosuppressive treatments for immunoglobulin A nephropathy: a meta-analysis of randomized controlled trials. Nephrology. 2004;9(4):177-185.

5. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1-150.

6. Koyama A, Igarashi M, Kobayashi M. Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases. Am J Kidney Dis. 1997;29(4):526-532.

7. Lee H, Kim DK, Oh KH, et al. Mortality of IgA nephropathy patients: a single center experience over 30 years. PLoS One. 2012;7(12):e51225.

8. Berthoux F, Mohey H, Laurent B, et al. Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol. 2011;22(4):75-761.

9. Le W, Liang S, Hu Y, et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant. 2012;27(4):1479-1485.

10. Barbour SJ, Cattran DC, Espino-Hernandez G, Hladunewich MA, Reich HN. Identifying the ideal metric of proteinuria as a predictor of renal outcome in idiopathic glomerulonephritis. Kidney Int. 2015;88(6):1392-1401.

11. Li X, Liu Y, Lv J, et al. Progression of IgA nephropathy under current therapy regimen in a Chinese population. Clin J Am Soc Nephrol. 2014;9(3):484-489.

12. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med. 2002;347(10):738-748.

13. Suzuki H, Kiryluk K, Novak J, et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011;22(10):1795-1803.

14. Itoh A, Iwase H, Takatani T, et al. Tonsillar IgA1 as a possible source of hypoglycosylated IgA1 in the serum of IgA nephropathy patients. Nephrol Dial Transplant. 2003;18(6):1108-1114.

15. Hotta O, Miyazaki M, Furuta T, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001;38(4):736-743.

16. Xie Y, Nishi S, Ueno M, et al. The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int. 2003;63(5):1861-1867.

17. Kawamura T, Yoshimura M, Miyazaki Y, et al. The Special IgA Nephropathy Study Group. A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Nephrol Dial Transplant. 2014;29(8):1546-1553.

18. Liu LL, Wang LN, Jiang Y, et al. Tonsillectomy for IgA nephropathy: a meta-analysis. Am J Kidney Dis. 2015;65(1):80-87.

19. Hirano K, Matsuzaiki K, Yasuda T, et al. Association between tonsillectomy and outcomes in patients with immunoglobulin A nephropathy. JAMA Netw Open. 2019;2(5):e194772.

20. Duan J, Liu D, Duan G, Liu Z. Long-term efficacy of tonsillectomy as a treatment in patients with IgA nephropathy: a meta-analysis. Int Urol Nephrol. 2017;49(1):103-112.

21. Maeda I, Hayashi T, Sato KK, et al. Tonsillectomy has beneficial effects on remission and progression of IgA nephropathy independent of steroid therapy. Nephrol Dial Transplant. 2012;27(7):2806-2813.

22. Komatsu H, Fujimoto S, Kikuchi M, Sato Y, Kitamura K. Tonsillectomy delays progression of advanced IgA nephropathy to end-stage kidney disease. Ren Fail. 2012;34(4):448-453.

23. Matsu S, Imai E, Horio M, et al. Collaborators developing the Japanese equation for estimated GFR: revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982-992.

24. Suzuki Y, Matsuzaiki K, Suzuki H, et al. Proposal of remission criteria for IgA nephropathy. Clin Exp Nephrol. 2014;18(3):481-486.

25. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452-458.

26. Tatematsu M, Yasuda Y, Morita Y, et al. Complete remission within 2 years predicts a good prognosis after methylprednisolone pulse therapy in patients with IgA nephropathy. Clin Exp Nephrol. 2012;16(6):883-891.

27. Hirano K, Kawamura T, Tsuibo N, et al. The predictive value of attenuated proteinuria at 1 year after steroid therapy for renal survival in patients with IgA nephropathy. Clin Exp Nephrol. 2013;17(4):555-562.

28. Sevillano AM, Gutierrez E, Yuste C, et al. Remission of hematuria improves renal survival in IgA nephropathy. J Am Soc Nephrol. 2017;28(10):3089-3099.

29. Sugiyama N, Masuda Y. Efficacy of tonsillectomy in eight IgA nephritis cases with chronic tonsillitis. Nitihentou-shi. 1983;22:49-60.

30. Somar S, Mitobe S, Himm T. A case of IgA nephropathy improving by tonsillectomy. Nitihentou-shi. 1983;22:133-137.

31. Hotta O, Furuta T, Chiba S, et al. A repeat biopsy study. Am J Kidney Dis. 2002;39(3):493-502.
32. Sato M, Adachi M, Kosukegawa H, et al. The size of palatine tonsils cannot be used to decide the indication of tonsillectomy for IgA nephropathy. *Clin Kidney J.* 2017;10(2):221-228.

33. Kawaguchi T, Ieiri N, Yamazaki S, et al. Clinical effectiveness of steroid pulse therapy combined with tonsillectomy in patients with immunoglobulin A nephropathy presenting glomerular hematuria and minimal proteinuria. *Nephrology.* 2010;15(1):116-123.

34. Miyazaki M, Hotta O, Komatsuda A, et al. Japanese Multicenter Study Group on Treatment of IgA Nephropathy (JST-IgAN). A multicenter prospective cohort study of tonsillectomy and steroid therapy in Japanese patients with IgA nephropathy: a 5-year report. *Contrib Nephrol.* 2007;157:94-98.

35. Lv J, Xu D, Perkovic V, et al; TESTING Study Group. Corticosteroid therapy in IgA nephropathy. *J Am Soc Nephrol.* 2012;23(6):1108-1116.

36. Rauen T, Eitner F, Fitzner C, et al. STOP-IgAN Investigators. Intensive supportive care plus immunosuppression in IgA nephropathy. *N Engl J Med.* 2015;373(23):2225-2236.

37. Miyawaki Y, Katsuyama T, Sada KE, et al. A retrospective observational study of glucocorticoid-induced diabetes mellitus with IgA nephropathy treated with tonsillectomy plus methylprednisolone pulse therapy. *PLoS One.* 2017;12(5):e0178018.

38. Hirano K, Amano H, Kawamura T, et al. Tonsillectomy reduces recurrence of IgA nephropathy in mesangial hypercellularity type categorized by the Oxford classification. *Clin Exp Nephrol.* 2016;20(3):425-432.

39. Kawamura T, Joh K, Okonogi H, et al; Study Group Special IgA Nephropathy. A histologic classification of IgA nephropathy for predicting long-term prognosis: emphasis on end-stage renal disease. *J Nephrol.* 2013;26(2):350-357.